Drug efflux by Breast Cancer Resistance Protein (BCRP) is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924

BACKGROUND: Preclinical investigations have identified insulin-like growth factor (IGF) signaling as a key mechanism for cancer growth and resistance to clinically useful therapies in multiple tumor types, including breast cancer. Thus, agents targeting and blocking IGF signaling have promise in the...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Hou, Xiaonan, Huang, Fei, Carboni, Joan M., Flatten, Karen, Asmann, Yan W., Eyck, Cynthia Ten, Nakanishi, Takeo, Tibodeau, Jennifer D., Ross, Douglas D., Gottardis, Marco M., Erlichman, Charles, Kaufmann, Scott H., Haluska, Paul
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3057506/
https://ncbi.nlm.nih.gov/pubmed/21220496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0438
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items